Role of ISGF3 in modulating the anti-hepatitis B virus activity of interferon-alpha in vitro

J Gastroenterol Hepatol. 2008 Nov;23(11):1747-61. doi: 10.1111/j.1440-1746.2007.04985.x. Epub 2007 Jun 7.

Abstract

Background and aim: Although interferon-alpha (IFN-alpha) is an effective treatment for hepatitis B virus (HBV) infection, its precise mechanism of action has not been identified. In this study, we investigated the role of signal transduction pathways in the activation of anti-HBV responses mediated by IFN-alpha.

Methods: Using an oligo microarray, we found that four genes in the IFN-alpha signal pathway were markedly upregulated by IFN-alpha in human hepatoma cells regardless of whether they had been transfected with a plasmid containing the HBV genome: signal transducers and activators of transcription 1 (STAT1), interferon regulatory factor-9 (IRF-9, also called ISGF3gamma or P48), IFN-alpha-inducible protein 15 (IFI-15) and IFN-alpha-inducible protein 6-16 (IFI-6-16). We also investigated the role of IFN-stimulated gene factor3 (ISGF3) complex in IFN-alpha-mediated anti-HBV responses in human hepatoma cells by measuring the mRNA of the three genes within ISGF3 (STAT1, STAT2 and IRF-9) using semiquantitative reverse-transcription PCR (RT-PCR), and expression of the three proteins by western blot, and the mRNA and protein of dsRNA-dependent protein kinase (PKR).

Results: STAT1, STAT2, IRF-9 and PKR mRNA as well as protein levels were upregulated by IFN-alpha treatment. When cells were pretreated with genistein, STAT1, STAT2 and IRF-9 mRNA levels remained unchanged after IFN-alpha stimulation, but PKR mRNA levels decreased, and the expression of the STAT1, P-STAT2, IRF-9 and PKR proteins decreased. Levels of HBV DNA decreased in the supernatants of cells treated with IFN-alpha, while ISGF3 levels increased. The quantity of HBV DNA remained unchanged by pretreating with genistein.

Conclusions: These observations suggested that the Janus tyrosine kinase-STAT (JAK-STAT) pathway may play a major role in mediating the effects of IFN-alpha against HBV, and that ISGF3 might be a key factor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology*
  • Cell Line, Tumor
  • Cytokines / metabolism
  • DNA, Viral / biosynthesis
  • Gene Expression Profiling / methods
  • Genistein / pharmacology
  • Hepatitis B Surface Antigens / metabolism
  • Hepatitis B e Antigens / metabolism
  • Hepatitis B virus / drug effects*
  • Hepatitis B virus / genetics
  • Hepatitis B virus / immunology
  • Hepatocytes / drug effects*
  • Hepatocytes / immunology
  • Hepatocytes / virology
  • Humans
  • Interferon alpha-2
  • Interferon-Stimulated Gene Factor 3, gamma Subunit / genetics
  • Interferon-Stimulated Gene Factor 3, gamma Subunit / metabolism*
  • Interferon-alpha / pharmacology*
  • Janus Kinases / antagonists & inhibitors
  • Janus Kinases / metabolism
  • Mitochondrial Proteins / metabolism
  • Oligonucleotide Array Sequence Analysis
  • Phosphorylation
  • Protein Kinase Inhibitors / pharmacology
  • RNA, Messenger / metabolism
  • Recombinant Proteins
  • STAT1 Transcription Factor / metabolism
  • STAT2 Transcription Factor / metabolism
  • Signal Transduction / drug effects*
  • Signal Transduction / genetics
  • Time Factors
  • Transfection
  • Ubiquitins / metabolism
  • Virus Replication / drug effects
  • eIF-2 Kinase / metabolism

Substances

  • Antiviral Agents
  • Cytokines
  • DNA, Viral
  • Hepatitis B Surface Antigens
  • Hepatitis B e Antigens
  • IFI6 protein, human
  • IRF9 protein, human
  • Interferon alpha-2
  • Interferon-Stimulated Gene Factor 3, gamma Subunit
  • Interferon-alpha
  • Mitochondrial Proteins
  • Protein Kinase Inhibitors
  • RNA, Messenger
  • Recombinant Proteins
  • STAT1 Transcription Factor
  • STAT1 protein, human
  • STAT2 Transcription Factor
  • STAT2 protein, human
  • Ubiquitins
  • ISG15 protein, human
  • Genistein
  • Janus Kinases
  • eIF-2 Kinase